The invention relates to a method for producing dialkylamido element compounds. In particular, the invention relates to a method for producing dialkylamido element compounds of the type E(NRR′).sub.x, wherein first WAIN is reacted with HNRR′ in order to form M[Al(NRR′).sub.4] and hydrogen, and then the formed M[Al(NRR′).sub.4] is reacted with EX.sub.x in order to form E(NRR′).sub.x and M[AlX.sub.4], wherein M=Li, Na, or K, R=C.sub.nH.sub.2n+1, where n=1 to 20, and independently thereof R′=C.sub.nH.sub.2n+1, where n=1 to 20, E is an element of the groups 3 to 15 of the periodic table of elements, X=F, Cl, Br, or I, and x=2, 3, 4 or 5.

The present invention relates to the use of novel adducts of general formula (I) TPP.sub.xTPOP.sub.(1-x), wherein TPP is triphenylphosphine, TPOP is triphenylphosphite and x is a real number between 0.05 and 0.9. These novel adducts are useful for the bromination of primary alcohols, in particular for the bromination of primary alcohols.

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. ##STR00001##
wherein: X is C or N with the proviso that when X is N, R.sup.1 does not exist; W is C or N with the proviso that when W is N, R.sup.2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of ##STR00002## Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. ##STR00003##
wherein: L and M are independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

The present invention relates to a method for producing an InP-based quantum dot precursor from a phosphorus source and an indium source, in which a silylphosphine compound represented by the following Formula (1) with a content of a compound represented by the following Formula (2) of 0.3 mol % or less is used as the phosphorus source. Further, the present invention provides a method for producing an InP-based quantum dot comprising heating an InP quantum dot precursor to a temperature of 200° C. or more and 350° C. or less to obtain an InP quantum dot.

##STR00001##

(R is as defined in the specification.)

The present invention relates to a method for producing an InP-based quantum dot precursor from a phosphorus source and an indium source, in which a silylphosphine compound represented by the following Formula (1) with a content of a compound represented by the following Formula (2) of 0.3 mol % or less is used as the phosphorus source. Further, the present invention provides a method for producing an InP-based quantum dot comprising heating an InP quantum dot precursor to a temperature of 200° C. or more and 350° C. or less to obtain an InP quantum dot.

##STR00001##

(R is as defined in the specification.)

Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.

Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.

The present invention relates to a lithium secondary battery. The lithium secondary battery includes a positive electrode including a positive active material; a negative electrode including a negative active material; and an electrolyte including a non-aqueous organic solvent, a lithium salt, and an additive including a compound represented by Chemical Formula 1. The negative active material includes Si at about 0.1 wt % to about 32 wt % in amount based on a total weight of the negative active material. ##STR00001## wherein, in Chemical Formula 1, A is a substituted or unsubstituted aliphatic chain or (—C.sub.2H.sub.4—O—C.sub.2H.sub.4-)n, and n is an integer from 1 to 10.

A non-aqueous electrolyte for a lithium-ion battery and a lithium-ion battery. The non-aqueous electrolyte comprises unsaturated phosphate compounds and unsaturated cyclic carboxylic acid anhydride compounds. The unsaturated phosphate compounds have the structure illustrated in structural formula 4; structural formula 4: R.sub.13, R.sub.11, and R.sub.12 are independently selected from hydrocarbon groups having 1-5 carbon atoms respectively, and at least one of R.sub.13, R.sub.11, and R.sub.12 is an unsaturated hydrocarbon group containing double bonds or triple bonds; the unsaturated cyclic carboxylic acid anhydride compounds have the structure illustrated in structural formula 5; structural formula 5: R.sub.14 is independently selected from vinylidene having 2-4 carbon atoms or fluoro-substituted vinylidene. By means of the synergistic effect of two compounds, the non-aqueous electrolyte has excellent high-temperature cycling performance and storage performance, and also has lower impedance and good low-temperature performance. ##STR00001##

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.